The scientific journal Nature recently published an article from Munich University Hospital which describes the long-term survival of baboons that had received a heart transplant from genetically modified pigs.1 This is an important step forward on the way to being able to give humans porcine heart transplants.

December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all ...

Medical artificial intelligence (AI) company Bay Labs announced a collaboration with Edwards Lifesciences focused on improving the detection of heart disease. The partnership involves multiple initiatives, including the development of new AI-powered algorithms in Bay Labs’ EchoMD measurement and interpretation software suite, the integration of EchoMD algorithms into Edwards Lifesciences’ CardioCare quality care navigation platform, and support for ongoing clinical studies at leading institutions.

New data from the Phase 3 CASSINI study showed a 60 percent reduction of venous thromboembolism (VTE, or blood clot) events with oral anticoagulant Xarelto (rivaroxaban) compared to placebo in high-risk patients with cancer. The composite primary endpoint of VTE occurrence did not reach statistical significance during the full study period. Bleeding rates were low, though higher with Xarelto.

Corindus Vascular Robotics Inc. announced that its CorPath technology was used to conduct the first-in-human (FIH) Telerobotic Intervention Study, Dec. 4 and 5, 2018, in India. This study represents the world’s first percutaneous coronary intervention (PCI) conducted from a remote location outside of the catherization lab.